Arrowhead Pharmaceuticals Inc. has announced the approval of inducement grants for 38 new employees as part of their compensation plan. Approved by the company's Board of Directors on July 22, 2025, these grants allow employees to receive up to 52,680 restricted stock units collectively. These grants are issued under NASDAQ Listing Rule 5635(c)(4) and are separate from the company's stockholder-approved equity incentive plans. The granted stock units will vest annually over a period of four years.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.